Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples